Core Insights - SBC Medical Group Holdings is transitioning from a domestic platform to a globally scalable model, with a focus on the U.S. market and long-term growth strategies [3][4] Financial Performance - Average revenue per visit increased by 11% year-over-year to $316 in Q4, indicating a recovery from previous revenue compression [4] - The company reported a disciplined transition year in 2025, with revenue decline due to structural changes, while net income grew by 9% and margins remained stable [4] Market Positioning - SBC Medical aims to differentiate itself in the fragmented U.S. aesthetic market through a system-driven approach that enhances clinical quality, customer retention, and operational efficiency [3][4] - The company has established a minority investment in OrangeTwist, marking its entry into the U.S. market [4] Business Model - SBC Medical operates a capital-light business model, achieving EBITDA margins above 40% across 283 locations with 6.63 million annual patient visits [4] - The company is focused on long-term growth initiatives, including AI-driven operational infrastructure and expansion into Japan's $34 billion longevity market [4] Strategic Initiatives - The company is actively expanding its global presence, particularly in the U.S. and Asia, through direct operations and medical tourism initiatives [5] - SBC Medical was listed on Nasdaq in September 2024 and included in the Russell 3000® Index in June 2025, enhancing its visibility in the market [5]